期刊
EMERGING INFECTIOUS DISEASES
卷 12, 期 1, 页码 48-54出版社
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid1201.051237
关键词
-
资金
- NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI065097, R01AI029579, R37AI029579] Funding Source: NIH RePORTER
- NCI NIH HHS [CA21765, P30 CA021765] Funding Source: Medline
- NIAID NIH HHS [R37 AI029579, AI065097, AI29579, F32 AI065097] Funding Source: Medline
Current vaccine strategies against influenza focus on generating robust antibody responses. Because of the high degree of antigenic drift among circulating influenza strains over the course of a year, vaccine strains must be reformulated specifically for each influenza season. The time delay from isolating the pandemic strain to large-scale vaccine production would be detrimental in a pandemic situation. A vaccine approach based on cell-mediated immunity that avoids some of these drawbacks is discussed here. Specifically, cell-mediated responses typically focus on peptides from internal influenza proteins, which are far less susceptible to antigenic variation. We review the literature on the role of CD4+ and CD8+ T cell-mediated immunity in influenza infection and the available data on the role of these responses in protection from highly pathogenic influenza infection. We discuss the advantages of developing a vaccine based on cell-mediated immune responses toward highly pathogenic influenza virus and potential problems arising from immune pressure.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据